BioLineRx (BLRX) Repors Publication of Encouraging BL-1040 Phase 1/2 Data
Tweet Send to a Friend
BioLineRx (NASDAQ: BLRX) announced publication of the results of a previous Phase 1/2 (pilot) study for IK-5001 (BL-1040), currently named ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
